Thanks for sharing @megamutts.
Very good news indeed, though I don't think they are referring to Ph2 data, I believe the 40/60% data is from the patients with locally advanced disease from Ph1b.
"In patients with locally advanced disease, which is the focus
of the phase II study, there were two complete responses (40
percent) and three partial responses (60 percent)."
though its interesting to note the below, which i think was previously mentioned in their announcements
"PTX-200 is now in a phase II trial in women with HER2-negative
locally advanced breast cancer. Five of the patients in the phase
Ib study qualify for assessment of phase II data. If at least
three complete responses are observed in the first 11 patients,
then the phase II trial will expand to another 15 patients. Two
complete responses have already been observed in the first five
patients, he said."
